Outlook Therapeutics, Inc. (NASDAQ:), a biopharmaceutical firm, as we speak introduced preliminary topline outcomes from its NORSE EIGHT scientific trial, which evaluated ONS-5010 for the therapy of moist age-related macular degeneration (moist AMD...
